Cerevance Media Center
Current News
May 16, 2023
Oral Presentation of Phase 1 Data on CVN766 at American Society of Clinical Psychopharmacology (ASCP)
Cerevance to present an oral presentation at the upcomingAmerican Society of Clinical Psychopharmacology (ASCP) conference, taking place in Miami, Florida, May 30 – June 2, 2023.
May 9, 2023
Cerevance to Present at Neurodegeneration: New Biology Guiding the Next Generation of Therapeutic Development
Cerevance today announced plans to present at the upcoming Neurodegeneration: New Biology Guiding the NextGeneration of Therapeutic Development conference, taking place in British Columbia, Canada, May 15 – 19, 2023.
April 13, 2023
Poster Presentation at the BNA International Festival of Neuroscience
Cerevance today announced a poster presentation at the British Neuroscience Association (BNA) 2023 International Festival of Neuroscience in Brighton, United Kingdom being held April 23-26, 2023
March 21, 2023
Cerevance to Present at Two Medicinal Chemistry Conferences
Cerevance to present at two upcoming medicinal chemistry conferences:
- 7th RSC-BMCS / SCI Symposium on Ion Channels as Therapeutic Targets held March 27-28 in Cambridge, UK
- Binding Kinetics and Mechanistic PK/PD Modeling in Early Drug Discovery Conference held March 27-28 in Cambridge, UK
News Archive
September 23, 2024
Cerevance to Participate in a Panel Discussion at Fierce Biotech Summit 2024
Cerevance chief executive officer, Craig Thompson, will participate in a panel at the Fierce Biotech Summit, taking place in Boston, MA from September 30 – October 1, 2024.
June 18, 2024
Cerevance Presents at The Federation of European Neuroscience Societies (FENS) Forum 2024
Cerevance to deliver a poster presentation at the upcoming Federation of European Neuroscience Societies (FENS) Forum 2024, taking place in Vienna, Austria, from June 25 – 29, 2024.
Ataxia-telangiectasia (A-T) is a rare neurodegenerative disease caused by mutations in the ataxia-telangiectasia mutated gene, leading to progressive neurological issues. Using Cerevance’s NETSseq platform, RNA from purified cerebellar cell types of A-T and control donors was analyzed and subsequently revealed significant astrocyte gene expression changes related to inflammation and immune response.
March 13, 2024
Cerevance Announces Presentation at Alzheimer’s Research UK Conference
February 27, 2024
Cerevance Announces Presentation at AD/PD™ 2024 International Conference
February 22, 2024
Cerevance to Participate at the TD Cowen 44th Annual Health Care Conference
Events Archive
December 1, 2020